Beijing Continent Pharmaceutical Co, Ltd.

Quick facts

Phase 3 pipeline

• Hydronidone (270mg) · Immunology/Rheumatology
  Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors.
• Hydronidone capsules · Immunology/Inflammation
  Hydronidone is a corticosteroid that reduces inflammation and suppresses immune responses by binding to glucocorticoid receptors.
• Hydronidone (Placebo Group)
  Hydronidone is a placebo control agent with no active pharmacological mechanism.
• The placebo capsules
  The placebo capsules are inert substances used as a control in clinical trials.

Phase 2 pipeline

• F573 for injection · Oncology
  F573 for injection is a monoclonal antibody targeting the PD-1 receptor.
• Pirfenidone Capsules（0mg）
• Pirfenidone Capsules （400 mg）
• Pirfenidone Capsules（600mg） · Respiratory
  Antifibrotic agent

Phase 1 pipeline

• [¹⁴C]Hydronidone
• F230 tablets
• F573
• Hydronidone capsules& Entecavir capsules

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Beijing Continent Pharmaceutical Co, Ltd. portfolio CI brief
• Beijing Continent Pharmaceutical Co, Ltd. pipeline updates RSS